TY  JOUR
TI  Selection of a genetically engineered biological drug for ankylosing spondylitis with extra-skeletal manifestations
KW  ankylosing spondylitis
KW  extraskeletal manifestations
KW  uveitis
KW  etanercept
KW  golimumab
JO  Clinical Medicine and Pharmacology
AU  Tushnikova, E.V.
PY  2021
IS  7
PB  LLC Information and publishing center Innovations and investments